Polymer Factory Sweden (publ) Interim report Q1 2025

First quarter, January-March 2025

• Polymer Factory achieved a significant milestone by securing a strategic order for our SpheriCal® products from a global biopharma leader

• Result for the period increased with 30% compared to same period last year

• The Company carried out a directed share issue during the quarter, targeting a limited group of investors with the aim of increasing working capital

Comments from CEO Mats Wallnér

In the first quarter of 2025, Polymer Factory achieved a significant milestone by securing a strategic order for our SpheriCal® products from a global biopharma leader headquartered in California, USA. To strengthen our financial position, we carried out a directed share issue during the quarter, targeting a limited group of investors with the aim of increasing working capital. At the same time, we have sharpened our focus on driving sales and optimizing our cost structure.

“Focus on Sales, Profitability, and Growth”

Strong Start to 2025 – Strategic Progress and Growing Commercial Momentum In the first quarter of 2025 Polymer Factory achieved a significant milestone by securing a strategic order for our SpheriCal® products from a global biopharma leader headquartered in California, USA. This customer is a key player in the life science, diagnostics, and applied markets – and this agreement marks an important step forward for both our technology and business development.

The order relates to material intended for product evaluation, creating a strong foundation for future collaboration and expanded commercial opportunities. We are proud to support such a prominent partner with our sophisticated SpheriCal® calibration standards and are optimistic about the potential this partnership holds.

Focus on Sales, Profitability, and Growth

To strengthen our financial position, we carried out a directed share issue during the quarter, targeting a limited group of investors with the aim of increasing working capital. At the same time, we have sharpened our focus on driving sales and optimizing our cost structure.

We are now approaching potential customers in a more structured and proactive manner, identifying where our products can deliver the greatest value. We have also initiated cost-reduction measures, with tangible results expected to begin emerging in Q2 2025.

SpheriCal® Attracting Global Interest

Our calibrant product line – including SpheriCal® – has experienced a marked uptick in commercial interest during the quarter. Several major international players have taken note of the product’s outstanding performance and reliability.

To support our long-term growth, we have consolidated our intellectual property strategy with a leading Nordic patent firm. This move enables faster decision-making, clearer communication, and stronger IP protection as we scale our business.

A Premium Product with Exceptional Value

SpheriCal® is not only technically advanced – it also holds significant commercial value. A single vial, priced at approximately €250, contains just 5 micrograms but can be used for 50 to 100 instrument calibrations. This corresponds to a market price of €50 million per gram. Based on current inventory levels, our SpheriCal® stock has a theoretical market value exceeding €5 billion.

Navigating Uncertainty with Confidence

Despite global turbulence and ongoing trade tensions, our business remains stable. To date, geopolitical developments have not significantly affected our operations. Our global customers continue to value the unique benefits our products provide, along with the deep expertise and capabilities within our team. As we move further into 2025, we do so with confidence, strategic partnerships, and a continued focus on growth, innovation, and profitability.

About Polymer Factory Polymer Factory was founded in 2006 at KTH Royal Institute of Technology and its Board of Directors have been essential in driving dendritic nanotechnology research to commercialization for almost 15 years – expertise that has been transferred to the Company’s products. Emerging from many years of cutting-edge research within the field, Polymer Factory today has, in the Company’s assessment, the world’s largest product portfolio of dendritic materials with customers ranging from Big Pharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. Polymer Factory has also used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments.

For more information, please contact:

Mats Wallnér, acting CEO

Phone: +46 (0) 70 951 95 06

E-mail: mats.wallner@polymerfactory.com  

This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 16 May 2025.